Corporate, Commercial & Regulatory

Impressive depth of specialised experience

Van Bael & Bellis advises multinational clients on corporate, commercial and regulatory issues in the EU and Belgium.

Discover our expertise
  • "The lawyers are excellent; very responsive and to the point."

    Chambers Europe

Latest news

Sign up for updates
    • 05/04/2019
    • News

    Van Bael & Bellis assists the retail industry in securing an injunction by the European Commission suspending Slovakia’s tax on the food retail sector

    On 2 April 2019, the European Commission opened an in-depth investigation into a tax on the food retail sector in Slovakia over concerns that the way in which the tax is structured gives some retailers a selective advantage over their competitors, thus involving State aid in breach of EU rules. At the same time, the Commission issued an injunction requiring Slovakia to suspend the application of the measure until the Commission has concluded its assessment under EU State aid rules. The complaints giving rise to the Commission’s afore-mentioned decisions were lodged in December 2018. Van Bael & Bellis counsel Gábor Báthory assisted the retail industry in this matter. Further details on this case can be found here.

    Read more
    • 29/03/2019
    • News

    Fifteen Member States Sign Agreements for Supply of Pandemic Influenza Vaccines under Umbrella of Joint Procurement Agreement

    On 28 March 2019 the European Commission announced that 15 EU Member States and the Commission signed framework contracts with the pharmaceutical firm Seqirus for the supply of pandemic influenza vaccines to 30 contracting authorities in these Member States in the event of an influenza pandemic (https://ec.europa.eu/health/sites/health/files/preparedness_response/docs/ev_20190328_memo_en.pdf). The agreements will run for at least 4 years and are subject to a possible extension of 2 more years. Under the agreements, Seqirus will not only supply vaccines but will also reserve part of its weekly manufacturing capacity and will be paid in return an annual preparedness fee. The agreements were concluded under the Joint Procurement Agreement (“JPA”), a framework established on the basis of Article 5 of Decision 1082/2013/EU tackling serious cross-border threats to health. A similar set of agreements was entered into in 2016 to organise the joint procurement of botulinum anti-toxin. A further series of agreements to expand the vaccine coverage is under preparation. Additional joint procurement procedures for diphtheria anti-toxin, tuberculin and Bacillus Calmette–Guérin (“BCG”) vaccines, and personal protective equipment are under consideration. The JPA was conceived of to improve the state of preparedness of Member States for serious cross-border threats to health, ensure equal treatment of patients affected and increase the buying power of Member States when anticipating emergency situations.

    Read more

Subscribe to our updates

Please select the practice areas you are interested in: *

Get in touch

Please fill out the form below along with your query and someone from the team will get back to you. Alternatively you can email [email protected]

Recommendations

  • The quality of the advice is great - we have been asking some complex questions and they have given clear and to-the-point advice and have been very proactive in providing alternative solutions.

    Chambers Europe
  • Van Bael & Bellis has ‘impressive knowledge of dispute resolution, including mediation’. The firm is notable for its strong regulatory and administrative law contentious practice as well as its impressive life sciences sector presence.

    Legal 500
  • They patiently try to understand the mentality of people in different cultures and pay full respect to that. This attitude is rare in a highly expert world. We are fully satisfied with their practice and the results therefrom.

    IFLR1000
  • They are very responsive, and experienced in pharma and compliance-related matters. They always indicate the timelines of the work they do and keep the client informed on the status of the work.

    Chambers Europe

Team focus

Van Bael & Bellis is well known for its client-centred approach, commitment to excellence, exceptional client service and personalised attention.

Get in touch with our Corporate, Commercial & Regulatory teams today

Recent publications

Sign up for updates
    • 17/05/2019
    • Articles

    Belgium - Medicine Shortages - New Developments

    On 14 May 2019 the head of the Federal Agency for Medicines and Health Products (“FAMHP”), Xavier De Cuyper, sent a letter to all stakeholders in the pharmaceutical supply chain explaining his organisation’s view on the effects of the Law of 7 April 2019 “modifying the Law of 25 March 1964 on medicines as regards the unavailability of medicines” (the “Letter” - see attached). The Letter has since been published on the FAMHP website.   The Law of 7 April 2019 introduces a range of measures to reduce medicine shortages in Belgium (see, Van Bael & Bellis Life Sciences Newsflash of 8 May 2019). The Letter focuses on the practical consequences of the specific rule that limits the categories of customers to which a wholesaler (“WS”) with a public-service WS status (groothandelaar-verdeler/grossiste-répartiteur) is allowed to supply. These groups of potential customers are (a) other WS with a public-service WS status; (b) community pharmacists; and (c) hospitals recognised under applicable rules. As a result, WS with a public service WS status will no longer be able to sell medicines abroad.   The Letter highlights what FAMHP considers to be the following practical effects: Suppliers will no longer be able to refuse supplies to WS with a public-service WS status who will have to meet their public-service obligations in Belgium at all times and for that purpose require reliable and uninterrupted sources of medicines. The Letter stresses that FAMHP will monitor and enforce the supply obligation.  WS with a public-service WS status can no longer sell abroad. To the extent their owners want to continue pursuing export activities, these will have to act through a distinct legal entity that will require a separate WS licence. FAMHP will also monitor the obligation imposed on WS with a public-service WS status only to supply the limited categories of customers defined by law. The status of community pharmacists and hospital pharmacists does not change. Holders of marketing authorisations are required to report the unavailability of specific medicines. Additionally, WS with a public-service WS status and pharmacies are urged to report medicines that as a practical matter are not available even though they do not feature on the dedicated website of medicines reported as unavailable by the marketing authorisation holders.   The Letter addresses the status of ordinary WS only in passing (for example, by indicating – as noted – that ordinary WS will still be able to engage in export activities). In reality, the role and status of ordinary WS does not change under the Law of 7 April 2019.

    Read more
    • 14/05/2019
    • Newsletters

    VBB on Belgian Business Law, Volume 2019, No. 04

    The April 2019 issue of our Belgian Business Law newsletter reporting on the latest developments in a range of areas, including competition, data protection, intellectual property and labour law. Please click below to read the issue.

    Read more
    • 08/05/2019
    • Articles

    Belgium - Medicine Shortages | Wholesaler-Distributors Curtailed

    Today’s Belgian Official Journal contains the text of the “Law of 7 April 2019 modifying the Law of 25 March 1964 on medicines as regards the unavailability of medicines” (Wet tot wijziging van de wet van 25 maart 1964 op de geneesmiddelen voor wat de onbeschikbaarheden van geneesmiddelen betreft / Loi modifiant la loi du 25 mars 1964 sur les médicaments en ce qui concerne les indisponibilités de médicaments) (the “Law”). The Law (i) allows the concept of “temporary cessation of supply of medicines” to be determined by Royal Decree; (ii) allows the Minister to make recommendations of suitable therapeutical alternatives in case of temporary shortages of specific medicines; (iii) allows wholesalers (“WS”) with a public-service WS status (groothandelaar-verdeler/grossiste-répartiteur) only to supply specific categories of clients, namely (a) other WS with a public-service WS status; (b) community pharmacists; and (c) hospitals recognised under applicable rules; and (iv) imposes particular shortage-related obligations on parallel traders which previously only applied to the marketing authorisation holders. The Federal Agency for Medicines and Health Products has already announced implementing rules that will define the unavailability of a medicine and the period within which the orders of a WS with a public-service WS status will have to be supplied ( NL / FR ) The statutory limitation of the authorised categories of clients of WS with a public-service WS status (which are all based in Belgium and service the Belgian market) is designed to ensure the steady supply of medicines to the Belgian market and, conversely, cut down on exports that threaten public health. Under specific conditions, that limitation will not apply to medicines earmarked for clinical trials. To be sure, unlike WS with a public-service WS status, marketing authorisation holders and regular wholesalers will still be able to sell abroad. Lastly, the Law implements European rules that combat the trade in falsified medicines by creating criminal sanctions for specific violations of Regulation 2016/161 which lays down safety features for the packaging of medicines for human use.

    Read more
Keep updated Sign up for VBB insights

Be the first amongst your peers to get the latest publications and insights in Corporate, Commercial & Regulatory law.